

Recent Advances in the Diagnosis and Treatment of Pituitary Tumors

Edited by

John A. Linfoot, M.D.

Recent Advances in the Diagnosis and Treatment of Pituitary Tumors

Edited by

John A. Linfoot, M.D.

Physician-In-Chief

Donner Pavilion

Lawrence Berkeley Laboratory

University of California

Berkeley, California

Raven Press ■ New York

Raven Press, 1140 Avenue of the Americas, New York, New York 10036

© 1979 by Raven Press Books, Ltd. All rights reserved. This book is protected by copyright. No part of it may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without the prior written permission of the publisher.

Made in the United States of America

Library of Congress Cataloging in Publication Data

Main entry under title:

Recent advances in the diagnosis and treatment of
pituitary tumors.

Includes bibliographies and index.

1. Pituitary body-Tumors. I. Linfoot, John A.

[DNLM: 1. Pituitary neoplasms-Diagnosis. 2. Pituitary neoplasms-Therapy. WK585 R295]

RC280.P5R42 616.9'92'47 79-14948

ISBN 0-89004-365-5

The material contained in this volume was submitted as previously unpublished material, except in the instances in which credit has been given to the source from which some of the illustrative material was derived.

Great care has been taken to maintain the accuracy of the information contained in the volume. However, Raven Press cannot be held responsible for errors or for any consequences arising from the use of the information contained herein.

Preface

This volume reviews the current state of the art and science in the diagnosis and treatment of human pituitary tumors—difficult and frustrating problems for most clinicians. Neuroendocrine and neuroradiological advances in this rapidly growing area have decreased the wide variability in diagnostic evaluation and, in general, have lessened morbidity and mortality. However, no single treatment has been demonstrated to be uniformly effective, and local experience largely determines the treatment offered the patient.

The basic anatomical, histological, and biochemical features of the hypothalamohypophyseal system are considered with respect to the pituitary tumors associated with acromegaly, Cushing's disease, and galactorrhea-amenorrhea syndrome. Chapters based on our own experience review neuroradiological and neuro-ophthalmological procedures. The clinical features and X-ray and laboratory evaluation of patients with pituitary tumors are presented at a clinical level. The indications, results, and complications of treatment with thermal, cryogenic, transcranial, subfrontal, and transsphenoidal microsurgical techniques; implantation hypophysectomy with ^{90}Y or ^{198}Au ; and teletherapy with alpha particles, protons, and photons (gamma or X-rays) are presented. We also discuss recent drug therapy, especially agents with dopaminergic activity which have been demonstrated to alter hormone secretion by functioning pituitary tumors. These comprehensive and authoritative presentations provide a forum for critically evaluating treatment and defining areas for future investigation.

This volume will be of interest to neurosurgeons, clinical and basic endocrinologists, neuroradiologists, and neurologists.

John A. Linfoot, M.D.

Contributors

Toshihiro Aono

*Second Division
Department of Medicine and Depart-
ments of Obstetrics and Gynecology
Medical Faculty
Kyoto University
Sakyo-ku, Kyoto 606 Japan*

Takeshi Asoo

*Second Division
Department of Medicine and Depart-
ments of Obstetrics and Gynecology
Medical Faculty
Kyoto University
Sakyo-ku, Kyoto 606 Japan*

L. Banks

*The Endocrine Unit and Department of
Radiology
The Royal Postgraduate Medical School
Hammersmith Hospital
London W12 OHS, England*

J. M. B. Bloodworth, Jr.

*Department of Pathology
University of Wisconsin
Madison, Wisconsin 53706*

Ayten Cangir

*Department of Pediatrics
M. D. Anderson Hospital and Tumor
Institute
Houston, Texas 77030*

J. Cassar

*The Endocrine Unit and Department of
Radiology
The Royal Postgraduate Medical School
Hammersmith Hospital
London W12 OHS, England*

Robert F. Casper

*Department of Reproductive Medicine
Research Center
School of Medicine
University of California, San Diego
La Jolla, California 92093*

R. Jeffrey Chang

*Reproductive Endocrinology Center
Department of Obstetrics, Gynecology,
and Reproductive Sciences
University of California
San Francisco, California 94143*

F. H. Doyle

*The Endocrine Unit and Department of
Radiology
The Royal Postgraduate Medical School
Hammersmith Hospital
London W12 OHS, England*

N. Donna Gaudette

*General Medical Research
3710 S.W. Veterans
Hospital Road
Portland, Oregon 97201*

Grant E. Gauger

*Department of Neurological
Surgery
University of California
San Francisco, California 94143*

Ernest M. Gold

*Section of Endocrinology
Department of Internal Medicine
University of California, Davis
Sacramento, California 95817*

Ira D. Goldfine

*Cell Biology Research
Laboratory
Mt. Zion Medical Center
San Francisco, California 94140*

Daniel K. Gray

*General Medical Research
3710 S.W. Veterans
Hospital Road
Portland, Oregon 97201*

Jules Hardy

*Service of Neurosurgery
Notre Dame Hospital and University of
Montreal
Montreal, Quebec, Canada*

Eva Horvath

*Department of Pathology
St. Michael's Hospital
University of Toronto
Toronto, Ontario, Canada*

Hiroo Imura

*Second Division
Department of Medicine and Department of
Obstetrics and Gynecology
Medical Faculty
Kyoto University
Sakyo-ku, Kyoto 606 Japan*

A. Jadresic

*The Endocrine Unit and Department of
Radiology
The Royal Postgraduate Medical School
Hammersmith Hospital
London W12 OHS, England*

Robert B. Jaffe

*Reproductive Endocrinology Center
Department of Obstetrics, Gynecology,
and Reproductive Sciences
University of California
San Francisco, California 94143*

Richard H. Jesse, Jr.

*Department of Head
and Neck Surgery
M. D. Anderson Hospital and Tumor
Institute
Houston, Texas 77030*

Graham F. Joplin

*The Endocrine Unit and Department of
Radiology
The Royal Postgraduate Medical School
Hammersmith Hospital
London W12 OHS, England*

Naoki Kageyama

*Second Division
Department of Medicine and Department of
Obstetrics and Gynecology
Medical Faculty
Kyoto University
Sakyo-ku, Kyoto 606 Japan*

Yuzuru Kato

*Second Division
Department of Medicine and Department of
Obstetrics and Gynecology
Medical Faculty
Kyoto University
Sakyo-ku, Kyoto 606 Japan*

W. F. Kelley

*The Endocrine Unit and Department of
Radiology
The Royal Postgraduate Medical School
Hammersmith Hospital
London W12 OHS, England*

John W. Kendall

*General Medical Research
3710 S.W. Veterans
Hospital Road
Portland, Oregon 97201*

William R. Keye, Jr.

*Reproductive Endocrinology Center
Department of Obstetrics, Gynecology,
and Reproductive Sciences
University of California
San Francisco, California 94143*

Raymond N. Kjellberg

*Departments of Neurosurgery
and Medicine
Massachusetts General Hospital
Boston, Massachusetts 02114*

Bernard Kliman

*Endocrine Unit
Massachusetts General Hospital
Boston, Massachusetts 02114*

J. Köbberling

*Department of Internal Medicine
Endocrine Unit
Medizinische Einrichtungen der Universität
Göttingen
3400 Göttingen, Germany*

Peter O. Kohler

*University of Arkansas Medical School
Little Rock, Arkansas 72201*

Kalman Kovacs

*Department of Pathology
St. Michael's Hospital
University of Toronto
Toronto, Ontario, Canada*

Dorothy T. Krieger

*Division of Endocrinology and Metabolism
Mt. Sinai School of Medicine
New York, New York 10029*

Keiichi Kurachi

*Second Division
Department of Medicine and Department of Obstetrics and Gynecology
Medical Faculty
Kyoto University
Sakyo-ku, Kyoto 606 Japan*

Akio Kuwayama

*Second Division
Department of Medicine and Department of Obstetrics and Gynecology
Medical Faculty
Kyoto University
Sakyo-ku, Kyoto 606 Japan*

John H. Lawrence

*Donner Laboratory
Lawrence Berkeley Laboratory
University of California
Berkeley, California 94720*

Urban S. Lewis

*Lutcher Brown Center for Diabetes and Endocrinology
Scripps Clinic and Research Foundation
La Jolla, California 92037*

Choh Hao Li

*Hormone Research Laboratory
University of California
San Francisco, California 94143*

Florence C. Li

*Department of Radiology
Kaiser Permanente Medical Center
Redwood City, California 94063*

John A. Linfoot

*Donner Pavilion
Lawrence Berkeley Laboratory
University of California
Berkeley, California 94720*

Moshe Maor

*Department of Radiotherapy
M. D. Anderson Hospital and Tumor Institute
Houston, Texas 77030*

K. Mashiter

*The Endocrine Unit and Department of Radiology
The Royal Postgraduate Medical School
Hammersmith Hospital
London W12 0HS, England*

Toru Motohashi

*Second Division
Department of Medicine and Department of Obstetrics and Gynecology
Medical Faculty
Kyoto University
Sakyo-ku, Kyoto 606 Japan*

William Odell

*Department of Medicine
Harbor-UCLA Medical Center
Torrance, California 90509*

Eric S. Orwoll

*General Medical Research
3710 S.W. Veterans
Hospital Road
Portland, Oregon 97201*

Fumimaro Oseko

*Second Division
Department of Medicine and Department of Obstetrics and Gynecology
Medical Faculty
Kyoto University
Sakyo-ku, Kyoto 606 Japan*

Robert W. Rand

*Department of Surgery
Division of Neurological Surgery
University of California School of Medicine
Los Angeles, California 90024*

Naguib A. Samaan

*Section of Endocrinology
M. D. Anderson Hospital and Tumor
Institute
Houston, Texas 77030*

Vincent A. Samperi

*Department of Physics
Section of Endocrinology
M. D. Anderson Hospital and Tumor
Institute
Houston, Texas 77030*

Gottfried Schwinn

*Department of Internal Medicine
Endocrine Unit
Medizinische Einrichtungen der Universität Göttingen
3400 Göttingen, Germany*

Glenn E. Sheline

*Department of Radiation Oncology
University of California
San Francisco, California 94143*

M. B. Sigel

*Lutcher Brown Center for Diabetes and
Endocrinology
Scripps Clinic and Research Foundation
La Jolla, California 92037*

Michael S. Taekman

*Department of Neurosurgery
University of California
San Francisco, California 94143*

Cornelius A. Tobias

*Biology and Medicine Division
Lawrence Berkeley Laboratory
Medical Physics Division
University of California
Berkeley, California 94704*

E. F. VanderLaan

*Lutcher Brown Center for Diabetes and
Endocrinology
Scripps Clinic and Research Foundation
La Jolla, California 92037*

Willard O. VanderLaan

*Lutcher Brown Center for Diabetes and
Endocrinology
Scripps Clinic and Research Foundation
La Jolla, California 92037*

Riccardo Vigneri

*Istituto di Patologia Medica II
University of Catania
Catania, Italy*

Eckehart Wiedemann

*Donner Pavilion
Lawrence Berkeley Laboratory
University of California
Berkeley, California 94720*

Charles B. Wilson

*Department of Neurological Surgery
University of California
San Francisco, California 94143*

Samuel S. C. Yen

*Department of Reproductive Medicine
Research Center
School of Medicine
University of California, San Diego
La Jolla, California 92093*

John R. Young

*Reproductive Endocrinology Center
Department of Obstetrics, Gynecology
and Reproductive Sciences
University of California
San Francisco, California 94143*

Nicholas T. Zervas

*Department of Neurosurgery
Harvard Medical School
Massachusetts General Hospital
Boston, Massachusetts 02114*

Contents

	Preface	v
1.	History of Pituitary Therapy at Donner Laboratory <i>John H. Lawrence</i>	1
2.	Anatomy of the Pituitary and Hypothalamus <i>Grant E. Gauger</i>	5
3.	Aspects of Recent Advances in Anterior Pituitary Hormones: Human Somatotropin and Lipotropin <i>Choh Hao Li</i>	17
4.	Recent Advances in Hypothalamic "Hormones" and Their Clinical Implications. <i>Robert F. Casper and Samuel S. C. Yen</i>	29
5.	Prolactin, Growth Hormone, and Problems <i>Willard P. VanderLaan, M. B. Sigel, E. F. VanderLaan, and Urban J. Lewis</i>	57
6.	Hormone Secretion During the Normal Menstrual Cycle. <i>Robert B. Jaffe, William R. Keye, Jr., R. Jeffrey Change, and John R. Young</i>	67
7.	ACTH: Recent Advances in Biochemistry and Physiology. <i>John W. Kendall, Daniel K. Gray, N. Donna Gaudette, and Eric S. Orwoll</i>	83
8.	Growth Hormone and Somatomedins <i>Eckehart Wiedemann</i>	93
9.	Thyroid Stimulating Hormone <i>William D. Odell</i>	111
10.	Neuroradiological Examination in the Diagnosis of Pituitary Adenomas <i>Florence C. Li and John A. Linfoot</i>	119
11.	Neuro-Ophthalmological Considerations in Pituitary Tumors <i>John A. Linfoot</i>	131
12.	Light and Electron Microscopy of Pituitary Tumors <i>J. M. B. Bloodworth, Jr., Kalman Kovacs, and Eva Horvath</i>	141

13.	Endocrine Evaluation of Patients with Nonfunctioning Pituitary Tumors	161
	<i>Peter O. Kohler</i>	
14.	Diagnosis of Cushing's Syndrome: Some Unfinished Business . .	171
	<i>Ernest M. Gold</i>	
15.	Hyperprolactinemia	189
	<i>Hiroo Imura, Yuzuru Kato, Fumimaro Oseko, Takeshi Asoo, and Toru Motohashi</i>	
16.	Acromegaly	207
	<i>John A. Linfoot</i>	
17.	Pituitary Radiation: Radiation Physics and Biology.	221
	<i>Cornelius A. Tobias</i>	
18.	Heavy Ion Therapy: Alpha Particle Therapy of Pituitary Tumors	245
	<i>John A. Linfoot</i>	
19.	Lifetime Effectiveness—A System of Therapy for Pituitary Adenomas, Emphasizing Bragg Peak Proton Hypophysectomy	269
	<i>Raymond N. Kjellberg and Bernard Kliman</i>	
20.	Role of Conventional Radiation Therapy in the Treatment of Functional Pituitary Tumors	289
	<i>Glenn E. Sheline</i>	
21.	Hypopituitarism After External Irradiation of Nasopharyngeal Cancer	315
	<i>Naguib A. Samaan, Moshe Maor, Vincent A. Sampiere, Ayten Cangir, and Richard H. Jesse, Jr.</i>	
22.	Implantation of Yttrium-90 or Gold-198 Seeds	331
	<i>Graham F. Joplin, L. Banks, J. Cassar, F. H. Doyle, H. Jadresic, W. F. Kelly, and K. Mashiter</i>	
23.	Pharmacological Therapy of Cushing's Disease and Nelson's Syndrome.	337
	<i>Dorothy T. Krieger</i>	
24.	Pharmacological Therapy of Acromegaly	341
	<i>Ira D. Goldfine and Riccardo Vigneri</i>	
25.	Long-Term Treatment of Acromegaly with Bromocriptine—Up to Four Years	347
	<i>Gottfried Schwinn and J. Köbberling</i>	

26.	Pharmacological Treatment of Hyperprolactinemia	355
	<i>Hiroo Imura, Yuzuru Kato, Fumimaro Oseko, Toru Motohashi,</i> <i>Keiichi Kurachi, Toshihiro Aono, Naoki Kageyama, and</i> <i>Akio Kuwayama</i>	
27.	Transfrontal Microsurgery for Tumors of the Sella and Parasellar Areas	365
	<i>Michael S. Taekman</i>	
28.	Transsphenoidal Microsurgical Treatment of Pituitary Tumors .	375
	<i>Jules Hardy</i>	
29.	Stereotaxic Cryohypophysectomy in Pituitary Tumors	389
	<i>Robert W. Rand</i>	
30.	Stereotaxic Thermal Surgery of the Pituitary	407
	<i>Nicholas T. Zervas</i>	
31.	Role of Transsphenoidal Microsurgery in the Primary and Secondary Management of Pituitary Tumors	419
	<i>Charles B. Wilson, John A. Linfoot, and Glenn E. Sheline</i>	
32.	Goals of Therapy	429
	<i>William D. Odell</i>	
	<i>Subject Index</i>	433

1

History of Pituitary Therapy at the Donner Pavilion

John H. Lawrence

*Donner Laboratory, University of California, Lawrence Berkeley Laboratory,
Berkeley, California 94720*

My interest in the pituitary goes back to the time when I wrote my first paper on the pituitary gland while working with Harvey Cushing (3,7,10). By coincidence, my first paper on the effect of irradiation with dense ionization or heavy particles was on the same program as Dr. Cushing who presented a paper on "pituitary basophilism," formerly called the pluriglandular syndrome. Finally, as an intern in surgery at the Peter Brigham Hospital, I evaluated the first patient in whom Dr. Cushing diagnosed "pituitary basophilism," now called Cushing's disease. This began a continuing interest in both the pituitary and heavy particle irradiation.

During these early years a series of studies using X-irradiation on animals and man was undertaken and later demonstrated the radioresistance of the hypophysis (8). Later, observations of a Wilson cloud chamber—which displayed dense ionization with protons compared to the weaker ionization of electrons, X-rays, and γ -rays—initiated dense ionization studies at the Lawrence Berkeley Laboratory. One could see the fine tracks in the background of the β -ray ionization and the very dense tracks from the ionization produced by protons as a result of collisions by neutrons. Studies were immediately begun on mice to see whether dose-for-dose dense ionization would produce a greater biological effect than ordinary X-ray ionization in tissue (4,9). Indeed this proved to be true (5), and safety standards were established for employees working with cyclotrons and reactors, allowing them only one-tenth of the then allowable X-ray dose exposure. Soon after the original studies on normal animals were concluded, studies were initiated on animals with tumors. It was found that there was a relatively greater increase in the biological effect of neutrons (dose for dose) than that produced by X-rays (6). This led to the early trial of neutrons in cancer therapy (12). Although we determined the greater effect of neutrons, the oxygen effect on ionizing irradiation was unknown. The tumors irradiated were relatively hypoxic (*in vitro*), which reduced the effectiveness of X-rays

and had little effect on the neutrons. Many years later, Cornelius Tobias (Chapter 17) and Professor Luis Alvarez performed experimental work with positively charged heavy particles employing carbon-14 ions accelerated from the 60-inch cyclotron (13). Since those early days there has been tremendous activity at the Donner Laboratory and the Lawrence Berkeley Laboratory on the use of heavy charged particles in experimental biology, biophysics, and investigative medical therapy (1,11).

After World War II cellular experiments with relatively low energy heavy particles such as argon, krypton, etc. (energy not sufficient to penetrate animal tissues) were carried out (2). Although the Bragg peak was known from the early studies with alpha particles with radium, these studies with low-energy particles showed that the dense ionization at the Bragg peak had a greater radiobiological effect (RBE). With the greater density and high energy at the Bragg peak, accelerated particles from the Bevalac can produce tissue ionizations as high as 100 keV per micron at any depth in tissue. This density brings down the oxygen effect from approximately three to slightly over one. Utilizing the Bevalac and Bragg peak of particles such as carbon, neon, and other nuclei (300 to 400 meV per nucleon), it will be possible to deliver larger doses more accurately to the pituitary than currently employed.

Finally, because of the pioneering work at the Donner Laboratory, the Biology and Medicine Division of the Lawrence Berkeley Laboratory, a broad program of pituitary and cancer research is being carried out with heavy particles at many other centers in this country and abroad.

REFERENCES

1. D'Angio, G. J., and Lawrence, J. H. (1963): Medical research with high-energy heavy particles. *Nucleonics*, 21:56-61.
2. D'Angio, G. J., Lawrence, J. H., Gottschalk, A., and Lyman, J. (1964): Relative efficiency of high-LET radiation (Bragg-peak lithium ions) on normal rabbit skin, using integral dose as a basis for comparison. *Nature*, 204:1267-1268.
3. Lawrence, J. H. (1935): The clinical symptoms and signs of dissecting aneurysm of the aorta; with report of a case diagnosed during life. *Int. Clin.*, 2:122-133.
4. Lawrence, J. H. (1938): Artificial radioactivity and neutron rays in biology and medicine. In: *Handbook of Physical Therapy*, pp. 1-18. A.M.A. Council on Physical Therapy, Chicago.
5. Lawrence, J. H., Aebersold, P. C., and Lawrence, E. O. (1936): Comparative effects of X rays and neutrons on normal and tumor tissue. *Proc. Natl. Acad. Sci. USA*, 22:543-557.
6. Lawrence, J. H., Aebersold, P. C., and Lawrence, E. O. (1937): *The Comparative Effects of Neutrons and X-rays on Normal and Neoplastic Tissue*. Am. Assoc. Adv. Sci. Occasional Publications No. 4, pp. 215-219.
7. Lawrence, J. H., and Dial, D. E. (1932): Effects of intravitreal injections of pituitrin and pilocarpine in dogs. *Proc. Soc. Exp. Biol. Med.*, 30:49-54.
8. Lawrence, J. H., Nelson, W. O., and Wilson, H. (1937): Roentgen irradiation of the hypophysis. *Radiology*, 29:446-454.
9. Lawrence, J. H., and Tennant, R. (1937): The comparative effects of neutrons and X-rays on the whole body. *J. Exp. Med.*, 66:667-688.
10. Lawrence, J. H., and Zimmerman, H. M. (1935): Pituitary basophilism report of a case. *Arch. Intern. Med.*, 55:745-759.

11. Sillesen, K., Lawrence, J. H., and Lyman, J. T. (1968): Heavy-particle ionization (He, Li, B, Ne) and the proliferative capacity of neoplastic cells in vivo. *Acta Isot. (Padova)*, 3:107-126.
12. Stone, R. S., Lawrence, J. H., and Aebersold, P. D. (1940): A preliminary report on the use of fast neutrons in the treatment of malignant disease. *Radiology*, 35:322-327.
13. Tobias, C. A., Anger, H. O., and Lawrence, J. H. (1952): Radiological use of high energy deuterons and alpha particles. *Am. J. Roentgenol. Radium Ther. Nucl. Med.*, 67:1-25.

2

Anatomy of the Pituitary and Hypothalamus

Grant E. Gauger

*Department of Neurological Surgery, University of California,
San Francisco, California 94143*

The human pituitary gland was first described in 1524 by the great Italian anatomist Berengario da Carpi, who had described aspects of the ventricular system of the brain during the preceding year. The name was given to the rounded structure lying within the small bony fossa of the skull base, and derived from a notion of mucus or other secretory product coming from the brain, a prophetic concept for the time. Later, in 1672, Schneider dismissed the idea of a relationship of the pituitary gland to production of phlegm, and embryologic studies led to the recognition of a remarkable double developmental origin of the adult pituitary gland, culminating in the description of the origin of cells of the anterior pituitary from the stomodeum of the embryo. There was subsequently increasing reference to the relationship of the pituitary gland to hormonal function.

The extension of the primitive oral cavity, Rathke's pouch, comes into contact with an evagination of the ventricular floor, destined to become the posterior pituitary or neurohypophysis. Therefore the fully developed pituitary gland, which measures approximately 6 by 10 by 13 mm, consists of two embryologically and histologically distinct tissues. A third recognizable component, the pars tuberalis—in man a thin anterior cellular investment of the neural stalk—derives from portions of Rathke's pouch and is of uncertain physiological significance. In the human the adenohypophysis accounts for approximately three-fourths of the 0.5-g weight of the pituitary gland.

The pituitary gland is surrounded by a double layer of dura within the sella turcica of the sphenoid bone. The development of a more intimate investment continuous with intracranial pia matter was described by Ciric (Fig. 1). The neural stalk, or infundibulum, descending from the hypothalamic floor overlying the sella, penetrates a firm transverse dural roof of the sella, which takes its rostral origin from the anterior wall of the sella at a level approximately 3 mm inferior to the bony sellar margin, the tuberculum (Fig. 2). The size of the aperture through which the stalk passes varies greatly; when of a large diameter, it sometimes permits herniation of overlying arachnoid membrane




FIG. 1. Continuity of pituitary capsule and cerebral pia mater. (From ref. 4, with permission.)

into the sellar cavity. The anterior wall of sella separates its contents from the sphenoid sinus. It is of variable thickness, but in approximately 70% of cases is 1.0 mm thick or less. As a result, neoplasms arising within sella more frequently erode the anterior wall, with extension into the sphenoid sinus, than the thicker posterior bony barrier of the sella. The thin anterior wall similarly provides ready surgical access to sellar contents, a fact recognized by Cushing, who early developed an anterior approach to the pituitary gland.

Laterally the sella is bounded by the cavernous sinuses and their neural and vascular structures. The looping carotid arteries are in closest approximation at the sella level, and carotid tortuosity and ectasia may result in an arterial approach to the midline, which is of surgical importance in intrasellar manipulations (Fig. 3). Lateral extensions of pituitary tumors may produce clinical syndromes resulting from compromise or destruction of structures within the cavernous sinuses, as detailed by Jefferson in a classic contribution. Further, the cavernous sinuses are interconnected by venous channels of variable size